Please assess the completion status of the following clinical trial:

Trial Title: Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 48 weeks of treatment in study RNA200103-201~Exclusion Criteria:~* Patients who were determined to be treatment failures in study RNA200103-201~* Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103-201~* Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103-201

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).